Exicure to issue 172,058 shares to settle $1.0M milestone

Exicure, Inc. announced its plan to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026. This share issuance will settle a $1.0 million clinical milestone payment obligation stemming from their License and Collaboration Agreement. The milestone was triggered by the successful completion of the Phase 2 clinical trial for Burixafor (GPC-100) and the formal submission of its Clinical Study Report to the U.S. Food and Drug Administration. The company stated that settling this payment with stock will help preserve cash and maintain financial flexibility.